Hennessy Advisors Inc. Sells 2,195 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Hennessy Advisors Inc. cut its stake in Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 16.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,471 shares of the company after selling 2,195 shares during the quarter. Hennessy Advisors Inc.’s holdings in Cellebrite DI were worth $137,000, according to its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of CLBT. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Cellebrite DI by 78.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,862 shares of the company’s stock worth $233,000 after purchasing an additional 11,771 shares in the last quarter. State of New Jersey Common Pension Fund D increased its stake in Cellebrite DI by 36.8% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 67,385 shares of the company’s stock worth $584,000 after purchasing an additional 18,119 shares in the last quarter. Josh Arnold Investment Consultant LLC purchased a new stake in Cellebrite DI in the fourth quarter worth $346,000. IGP Investments GPLP LP acquired a new stake in Cellebrite DI in the fourth quarter worth $182,619,000. Finally, Trexquant Investment LP increased its position in shares of Cellebrite DI by 297.1% in the fourth quarter. Trexquant Investment LP now owns 261,749 shares of the company’s stock worth $2,267,000 after acquiring an additional 195,841 shares during the period. Institutional investors own 45.88% of the company’s shares.

Cellebrite DI Stock Performance

CLBT opened Friday at $17.15. The stock has a fifty-day moving average of $13.12 and a 200-day moving average of $11.81. The company has a market cap of $3.53 billion, a price/earnings ratio of -29.57, a price/earnings/growth ratio of 1.97, and a beta of 1.50. Cellebrite DI Ltd. has a fifty-two week low of $6.36 and a fifty-two week high of $17.28.

Cellebrite DI (NASDAQ: CLBT – Get Free Report) last released its quarterly earnings results on Thursday, August 15. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.08 by $0.02. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 515.14%. The company had revenue of $95.70 million during the quarter, compared to analysts’ expectations of $91.94 million. During the same quarter in the prior year, the company earned $0.05 EPS. The company’s revenue increased by 24.8% year over year. On average, equities research analysts predict that Cellebrite DI Ltd. will post 0.38 EPS for the current fiscal year.

Analysts set new price targets

A number of brokerages have recently issued reports on CLBT. JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Craig Hallum increased their price target on Cellebrite DI from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Lake Street Capital increased their price target on Cellebrite DI from $13.50 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Deutsche Bank Aktiengesellschaft increased their price target on Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Bank of America raised their price objective on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a report on Friday, August 16th. Seven equities analysts have rated the stock with a “buy” rating. According to data from MarketBeat, Cellebrite DI currently has an average rating of “Buy” and a consensus price target of $17.33.

View our latest research report on CLBT

Cellebrite DI profile

(Free Report)

Cellebrite DI Ltd. develops solutions for regulatory investigations in Europe, the Middle East, Africa, the Americas and Asia Pacific. The company’s DI solutions enable users to collect, review, analyze and manage digital data throughout the investigation cycle for regulatory investigations used in a variety of cases including child exploitation, homicide, counter-terrorism, border control, sexual crimes, human trafficking, corporate security, cryptocurrency and intellectual property theft.

Featured Stories

Want to know which other hedge funds have CLBT in their portfolio? Visit HoldingsChannel.com for the latest 13F filings and insider transactions for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).

Get daily news and reviews for Cellebrite DI – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Cellebrite DI and related companies with MarketBeat.com’s FREE daily email newsletter.